25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CureVac NV
Buy, Hold or Sell?

Let's analyze Curevac together

I guess you are interested in CureVac NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of CureVac NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about CureVac NV

I send you an email if I find something interesting about CureVac NV.

1. Quick Overview

1.1. Quick analysis of Curevac (30 sec.)










1.2. What can you expect buying and holding a share of Curevac? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.68
Expected worth in 1 year
€0.47
How sure are you?
19.0%

+ What do you gain per year?

Total Gains per Share
€-1.21
Return On Investment
-49.6%

For what price can you sell your share?

Current Price per Share
€2.45
Expected price per share
€2.11 - €2.816
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Curevac (5 min.)




Live pricePrice per Share (EOD)
€2.45
Intrinsic Value Per Share
€-11.70 - €-13.18
Total Value Per Share
€-10.02 - €-11.50

2.2. Growth of Curevac (5 min.)




Is Curevac growing?

Current yearPrevious yearGrowGrow %
How rich?$397.2m$664.3m-$152.1m-29.7%

How much money is Curevac making?

Current yearPrevious yearGrowGrow %
Making money-$72.8m-$79.3m$6.4m8.9%
Net Profit Margin-438.0%-805.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Curevac (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#151 / 958

Most Revenue
#227 / 958

Most Profit
#891 / 958

Most Efficient
#626 / 958
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Curevac?

Welcome investor! Curevac's management wants to use your money to grow the business. In return you get a share of Curevac.

First you should know what it really means to hold a share of Curevac. And how you can make/lose money.

Speculation

The Price per Share of Curevac is €2.448. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Curevac.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Curevac, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.68. Based on the TTM, the Book Value Change Per Share is €-0.30 per quarter. Based on the YOY, the Book Value Change Per Share is €0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Curevac.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.34-14.0%-0.32-13.3%-0.23-9.3%-0.27-10.9%-0.26-10.6%
Usd Book Value Change Per Share-0.33-13.5%-0.32-13.1%0.031.2%0.093.6%0.083.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.33-13.5%-0.32-13.1%0.031.2%0.093.6%0.083.4%
Usd Price Per Share3.27-4.23-7.95-8.15-7.76-
Price to Earnings Ratio-2.38--3.60--8.74--51.13--48.69-
Price-to-Total Gains Ratio-9.90--14.77-252.92--38.84--38.84-
Price to Book Ratio1.84-1.82-2.69-2.69-2.56-
Price-to-Total Gains Ratio-9.90--14.77-252.92--38.84--38.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.5809264
Number of shares387
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.320.09
Usd Total Gains Per Share-0.320.09
Gains per Quarter (387 shares)-123.8234.26
Gains per Year (387 shares)-495.28137.06
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-495-5050137127
20-991-10000274264
30-1486-14950411401
40-1981-19900548538
50-2476-24850685675
60-2972-29800822812
70-3467-34750959949
80-3962-3970010961086
90-4458-4465012341223
100-4953-4960013711360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.013.03.020.0%4.013.04.019.0%4.013.04.019.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.013.03.020.0%4.013.04.019.0%4.013.04.019.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of CureVac NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.313-0.303-3%0.029-1186%0.084-472%0.080-491%
Book Value Per Share--1.6802.166-22%2.809-40%2.237-25%2.130-21%
Current Ratio--2.2872.667-14%4.704-51%3.092-26%2.945-22%
Debt To Asset Ratio--0.3240.326-1%0.310+4%0.497-35%0.473-32%
Debt To Equity Ratio--0.4790.487-2%0.455+5%0.530-10%0.505-5%
Dividend Per Share----0%-0%-0%-0%
Eps---0.325-0.308-5%-0.216-34%-0.254-22%-0.246-24%
Free Cash Flow Per Share---0.429-0.363-15%-0.362-16%-0.225-47%-0.220-49%
Free Cash Flow To Equity Per Share---0.435-0.371-15%-0.035-92%-0.051-88%-0.054-88%
Gross Profit Margin--1.0011.0020%1.0010%1.021-2%1.021-2%
Intrinsic Value_10Y_max---13.177--------
Intrinsic Value_10Y_min---11.700--------
Intrinsic Value_1Y_max---1.984--------
Intrinsic Value_1Y_min---1.949--------
Intrinsic Value_3Y_max---5.455--------
Intrinsic Value_3Y_min---5.218--------
Intrinsic Value_5Y_max---8.316--------
Intrinsic Value_5Y_min---7.763--------
Market Cap549120672.000-27%694924772.000899386983.000-23%1690822853.500-59%1734474357.900-60%1651880340.857-58%
Net Profit Margin---5.025-4.380-13%-8.052+60%-6.148+22%-6.176+23%
Operating Margin---5.148-4.433-14%-7.995+55%-6.020+17%-6.051+18%
Operating Ratio--6.1485.642+9%9.279-34%7.236-15%7.267-15%
Pb Ratio1.458-27%1.8451.817+2%2.690-31%2.689-31%2.560-28%
Pe Ratio-1.883+21%-2.383-3.598+51%-8.740+267%-51.128+2046%-48.693+1944%
Price Per Share2.448-27%3.0984.010-23%7.538-59%7.732-60%7.364-58%
Price To Free Cash Flow Ratio-1.426+21%-1.805-3.035+68%-5.514+205%-3.269+81%-3.113+72%
Price To Total Gains Ratio-7.827+21%-9.905-14.768+49%252.919-104%-38.835+292%-38.835+292%
Quick Ratio--2.1912.472-11%4.318-49%3.007-27%2.864-24%
Return On Assets---0.131-0.099-24%-0.084-36%-0.081-38%-0.077-41%
Return On Equity---0.194-0.149-23%-0.125-35%-0.123-36%-0.149-23%
Total Gains Per Share---0.313-0.303-3%0.029-1186%0.084-472%0.080-491%
Usd Book Value--397212232.450512205473.305-22%664390076.025-40%528998381.206-25%503807982.101-21%
Usd Book Value Change Per Share---0.330-0.320-3%0.030-1186%0.089-472%0.084-491%
Usd Book Value Per Share--1.7712.283-22%2.962-40%2.358-25%2.246-21%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.343-0.325-5%-0.227-34%-0.267-22%-0.259-24%
Usd Free Cash Flow---101478708.166-85776959.225-15%-85551173.500-16%-50618873.845-50%-49457344.938-51%
Usd Free Cash Flow Per Share---0.452-0.382-15%-0.381-16%-0.238-47%-0.232-49%
Usd Free Cash Flow To Equity Per Share---0.458-0.391-15%-0.037-92%-0.054-88%-0.057-88%
Usd Market Cap578937924.490-27%732659187.120948223696.177-23%1782634534.445-59%1828656315.534-60%1741577443.366-58%
Usd Price Per Share2.581-27%3.2664.227-23%7.947-59%8.152-60%7.764-58%
Usd Profit---76868921.276-72897866.061-5%-79384836.375+3%-65618394.357-15%-63563471.978-17%
Usd Revenue--15296854.51517225411.176-11%9912792.175+54%16194732.135-6%15582000.643-2%
Usd Total Gains Per Share---0.330-0.320-3%0.030-1186%0.089-472%0.084-491%
 EOD+3 -5MRQTTM+4 -30YOY+7 -275Y+8 -2610Y+8 -26

3.3 Fundamental Score

Let's check the fundamental score of CureVac NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.883
Price to Book Ratio (EOD)Between0-11.458
Net Profit Margin (MRQ)Greater than0-5.025
Operating Margin (MRQ)Greater than0-5.148
Quick Ratio (MRQ)Greater than12.191
Current Ratio (MRQ)Greater than12.287
Debt to Asset Ratio (MRQ)Less than10.324
Debt to Equity Ratio (MRQ)Less than10.479
Return on Equity (MRQ)Greater than0.15-0.194
Return on Assets (MRQ)Greater than0.05-0.131
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of CureVac NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.185
Ma 20Greater thanMa 502.575
Ma 50Greater thanMa 1002.673
Ma 100Greater thanMa 2002.859
OpenGreater thanClose2.550
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Fundamental data was last updated by Penke on 2024-11-13 08:21:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Curevac earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • A Net Profit Margin of -502.5% means that €-5.03 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CureVac NV:

  • The MRQ is -502.5%. The company is making a huge loss. -2
  • The TTM is -438.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-502.5%TTM-438.0%-64.5%
TTM-438.0%YOY-805.2%+367.2%
TTM-438.0%5Y-614.8%+176.7%
5Y-614.8%10Y-617.6%+2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-502.5%-124.9%-377.6%
TTM-438.0%-208.9%-229.1%
YOY-805.2%-207.8%-597.4%
5Y-614.8%-351.9%-262.9%
10Y-617.6%-473.1%-144.5%
4.3.1.2. Return on Assets

Shows how efficient Curevac is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • -13.1% Return on Assets means that Curevac generated €-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CureVac NV:

  • The MRQ is -13.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.1%TTM-9.9%-3.1%
TTM-9.9%YOY-8.4%-1.6%
TTM-9.9%5Y-8.1%-1.8%
5Y-8.1%10Y-7.7%-0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.1%-10.7%-2.4%
TTM-9.9%-11.7%+1.8%
YOY-8.4%-11.2%+2.8%
5Y-8.1%-12.6%+4.5%
10Y-7.7%-14.4%+6.7%
4.3.1.3. Return on Equity

Shows how efficient Curevac is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • -19.4% Return on Equity means Curevac generated €-0.19 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CureVac NV:

  • The MRQ is -19.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.4%TTM-14.9%-4.5%
TTM-14.9%YOY-12.5%-2.3%
TTM-14.9%5Y-12.3%-2.6%
5Y-12.3%10Y-14.9%+2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.4%-13.8%-5.6%
TTM-14.9%-15.8%+0.9%
YOY-12.5%-13.6%+1.1%
5Y-12.3%-18.6%+6.3%
10Y-14.9%-19.1%+4.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of CureVac NV.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Curevac is operating .

  • Measures how much profit Curevac makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • An Operating Margin of -514.8% means the company generated €-5.15  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CureVac NV:

  • The MRQ is -514.8%. The company is operating very inefficient. -2
  • The TTM is -443.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-514.8%TTM-443.3%-71.5%
TTM-443.3%YOY-799.5%+356.2%
TTM-443.3%5Y-602.0%+158.7%
5Y-602.0%10Y-605.1%+3.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-514.8%-258.6%-256.2%
TTM-443.3%-304.6%-138.7%
YOY-799.5%-223.5%-576.0%
5Y-602.0%-389.5%-212.5%
10Y-605.1%-497.7%-107.4%
4.3.2.2. Operating Ratio

Measures how efficient Curevac is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 6.15 means that the operating costs are €6.15 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of CureVac NV:

  • The MRQ is 6.148. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.642. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ6.148TTM5.642+0.506
TTM5.642YOY9.279-3.637
TTM5.6425Y7.236-1.595
5Y7.23610Y7.267-0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1482.760+3.388
TTM5.6423.393+2.249
YOY9.2793.299+5.980
5Y7.2364.814+2.422
10Y7.2676.536+0.731
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of CureVac NV.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Curevac is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.29 means the company has €2.29 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of CureVac NV:

  • The MRQ is 2.287. The company is able to pay all its short-term debts. +1
  • The TTM is 2.667. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.287TTM2.667-0.380
TTM2.667YOY4.704-2.037
TTM2.6675Y3.092-0.426
5Y3.09210Y2.945+0.147
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2873.709-1.422
TTM2.6673.886-1.219
YOY4.7044.684+0.020
5Y3.0925.946-2.854
10Y2.9456.274-3.329
4.4.3.2. Quick Ratio

Measures if Curevac is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • A Quick Ratio of 2.19 means the company can pay off €2.19 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CureVac NV:

  • The MRQ is 2.191. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.472. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.191TTM2.472-0.281
TTM2.472YOY4.318-1.846
TTM2.4725Y3.007-0.536
5Y3.00710Y2.864+0.143
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1913.199-1.008
TTM2.4723.497-1.025
YOY4.3184.549-0.231
5Y3.0075.897-2.890
10Y2.8646.437-3.573
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of CureVac NV.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Curevac assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Curevac to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.32 means that Curevac assets are financed with 32.4% credit (debt) and the remaining percentage (100% - 32.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of CureVac NV:

  • The MRQ is 0.324. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.326. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.324TTM0.326-0.003
TTM0.326YOY0.310+0.017
TTM0.3265Y0.497-0.171
5Y0.49710Y0.473+0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3240.350-0.026
TTM0.3260.347-0.021
YOY0.3100.312-0.002
5Y0.4970.365+0.132
10Y0.4730.382+0.091
4.5.4.2. Debt to Equity Ratio

Measures if Curevac is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • A Debt to Equity ratio of 47.9% means that company has €0.48 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CureVac NV:

  • The MRQ is 0.479. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.487. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.479TTM0.487-0.008
TTM0.487YOY0.455+0.032
TTM0.4875Y0.530-0.043
5Y0.53010Y0.505+0.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4790.393+0.086
TTM0.4870.437+0.050
YOY0.4550.374+0.081
5Y0.5300.450+0.080
10Y0.5050.493+0.012
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Curevac generates.

  • Above 15 is considered overpriced but always compare Curevac to the Biotechnology industry mean.
  • A PE ratio of -2.38 means the investor is paying €-2.38 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CureVac NV:

  • The EOD is -1.883. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.383. Based on the earnings, the company is expensive. -2
  • The TTM is -3.598. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.883MRQ-2.383+0.500
MRQ-2.383TTM-3.598+1.216
TTM-3.598YOY-8.740+5.141
TTM-3.5985Y-51.128+47.530
5Y-51.12810Y-48.693-2.435
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.883-2.225+0.342
MRQ-2.383-2.362-0.021
TTM-3.598-3.066-0.532
YOY-8.740-3.335-5.405
5Y-51.128-6.032-45.096
10Y-48.693-6.575-42.118
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CureVac NV:

  • The EOD is -1.426. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.805. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.035. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.426MRQ-1.805+0.379
MRQ-1.805TTM-3.035+1.230
TTM-3.035YOY-5.514+2.479
TTM-3.0355Y-3.269+0.234
5Y-3.26910Y-3.113-0.156
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.426-3.073+1.647
MRQ-1.805-3.177+1.372
TTM-3.035-3.575+0.540
YOY-5.514-4.527-0.987
5Y-3.269-8.367+5.098
10Y-3.113-9.230+6.117
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Curevac is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.84 means the investor is paying €1.84 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of CureVac NV:

  • The EOD is 1.458. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.845. Based on the equity, the company is underpriced. +1
  • The TTM is 1.817. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.458MRQ1.845-0.387
MRQ1.845TTM1.817+0.027
TTM1.817YOY2.690-0.872
TTM1.8175Y2.689-0.871
5Y2.68910Y2.560+0.128
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4581.893-0.435
MRQ1.8452.003-0.158
TTM1.8172.302-0.485
YOY2.6902.390+0.300
5Y2.6893.666-0.977
10Y2.5604.354-1.794
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets557,164
Total Liabilities180,409
Total Stockholder Equity376,755
 As reported
Total Liabilities 180,409
Total Stockholder Equity+ 376,755
Total Assets = 557,164

Assets

Total Assets557,164
Total Current Assets251,723
Long-term Assets305,441
Total Current Assets
Cash And Cash Equivalents 202,634
Short-term Investments 3,735
Net Receivables 34,784
Other Current Assets 13,847
Total Current Assets  (as reported)251,723
Total Current Assets  (calculated)255,001
+/- 3,278
Long-term Assets
Property Plant Equipment 276,414
Goodwill -16
Intangible Assets 26,848
Long-term Assets Other 1,656
Long-term Assets  (as reported)305,441
Long-term Assets  (calculated)304,902
+/- 538

Liabilities & Shareholders' Equity

Total Current Liabilities110,067
Long-term Liabilities70,342
Total Stockholder Equity376,755
Total Current Liabilities
Short-term Debt 5,074
Accounts payable 7,517
Other Current Liabilities 48,969
Total Current Liabilities  (as reported)110,067
Total Current Liabilities  (calculated)61,560
+/- 48,507
Long-term Liabilities
Capital Lease Obligations 39,035
Long-term Liabilities  (as reported)70,342
Long-term Liabilities  (calculated)39,035
+/- 31,307
Total Stockholder Equity
Common Stock26,934
Retained Earnings -1,710,082
Accumulated Other Comprehensive Income -146
Other Stockholders Equity 2,060,050
Total Stockholder Equity (as reported)376,755
Total Stockholder Equity (calculated)376,755
+/-0
Other
Capital Stock26,918
Cash and Short Term Investments 202,634
Common Stock Shares Outstanding 224,313
Current Deferred Revenue48,507
Liabilities and Stockholders Equity 557,165
Net Debt -163,576
Net Invested Capital 376,534
Net Working Capital 141,573
Property Plant and Equipment Gross 276,252
Short Long Term Debt Total 39,058



6.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-03-31
> Total Assets 
0
0
130,620
155,656
0
1,021,907
1,511,356
0
1,801,045
1,663,127
1,158,242
1,026,653
925,820
910,512
860,472
973,672
899,480
842,566
788,899
690,433
557,164
557,164690,433788,899842,566899,480973,672860,472910,512925,8201,026,6531,158,2421,663,1271,801,04501,511,3561,021,9070155,656130,62000
   > Total Current Assets 
60,633
0
57,175
60,108
44,892
915,500
1,389,854
1,322,593
1,608,942
1,454,094
940,019
789,289
675,589
622,282
584,029
686,916
603,210
536,833
478,775
377,885
251,723
251,723377,885478,775536,833603,210686,916584,029622,282675,589789,289940,0191,454,0941,608,9421,322,5931,389,854915,50044,89260,10857,175060,633
       Cash And Cash Equivalents 
-60,633
0
30,684
43,474
-44,892
892,399
1,322,593
-1,322,593
1,355,812
1,060,971
811,464
658,203
573,566
540,865
495,797
617,519
537,925
464,145
402,784
300,152
202,634
202,634300,152402,784464,145537,925617,519495,797540,865573,566658,203811,4641,060,9711,355,812-1,322,5931,322,593892,399-44,89243,47430,6840-60,633
       Short-term Investments 
121,266
0
1,458
1,418
89,784
1,129
2,619
2,645,186
40,107
7,712
4,648
4,664
3,608
2,599
4,487
3,069
5,354
3,455
2,661
3,803
3,735
3,7353,8032,6613,4555,3543,0694,4872,5993,6084,6644,6487,71240,1072,645,1862,6191,12989,7841,4181,4580121,266
       Net Receivables 
0
0
17,686
4,832
0
535
1,822
4,894
4,894
9,632
18,504
28,025
13,341
6,170
39,437
5,843
15,905
21,750
35,921
38,133
34,784
34,78438,13335,92121,75015,9055,84339,4376,17013,34128,02518,5049,6324,8944,8941,82253504,83217,68600
       Other Current Assets 
0
0
1,150
4,959
0
20,011
48,289
0
145,217
234,899
49,244
72,281
71,833
64,780
5,345
25,597
11,878
14,296
15,250
-1
13,847
13,847-115,25014,29611,87825,5975,34564,78071,83372,28149,244234,899145,217048,28920,01104,9591,15000
   > Long-term Assets 
-60,633
0
73,445
95,548
-44,892
106,407
121,502
-1,322,593
192,103
209,033
218,223
237,364
250,231
288,230
276,443
286,756
296,270
305,732
310,123
312,548
305,441
305,441312,548310,123305,732296,270286,756276,443288,230250,231237,364218,223209,033192,103-1,322,593121,502106,407-44,89295,54873,4450-60,633
       Property Plant Equipment 
0
0
66,780
87,232
0
94,057
104,791
168,104
168,104
192,743
200,393
221,311
235,011
251,461
241,702
253,163
261,570
272,217
278,855
279,025
276,414
276,414279,025278,855272,217261,570253,163241,702251,461235,011221,311200,393192,743168,104168,104104,79194,057087,23266,78000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
30
13
12,463
-75
-8
-48
12,473
0
-16
-16012,473-48-8-7512,4631330000000000000
       Intangible Assets 
0
0
5,698
6,120
0
10,138
14,146
0
16,196
13,572
13,238
12,636
12,251
33,762
19,315
30,675
31,708
30,517
15,882
31,324
26,848
26,84831,32415,88230,51731,70830,67519,31533,76212,25112,63613,23813,57216,196014,14610,13806,1205,69800
       Long-term Assets Other 
-60,633
0
967
2,027
-44,892
2,147
1,086
-1,322,593
7,454
2,351
1,216
1,717
1,663
1,688
1,666
1,697
1,704
1,748
-14,168
1,678
1,656
1,6561,678-14,1681,7481,7041,6971,6661,6881,6631,7171,2162,3517,454-1,322,5931,0862,147-44,8922,0279670-60,633
> Total Liabilities 
0
0
173,422
199,313
0
260,557
800,009
0
965,727
967,833
469,766
351,795
302,618
285,524
327,219
260,273
250,433
240,301
271,532
243,519
180,409
180,409243,519271,532240,301250,433260,273327,219285,524302,618351,795469,766967,833965,7270800,009260,5570199,313173,42200
   > Total Current Liabilities 
0
0
28,086
36,493
0
110,525
247,622
814,001
814,001
814,056
357,734
237,835
195,633
172,352
156,225
90,298
156,276
150,679
186,543
167,932
110,067
110,067167,932186,543150,679156,27690,298156,225172,352195,633237,835357,734814,056814,001814,001247,622110,525036,49328,08600
       Short-term Debt 
0
0
2,004
3,088
0
2,921
3,234
0
3,143
3,310
3,469
4,109
4,278
4,652
4,980
5,058
5,205
5,534
5,009
5,088
5,074
5,0745,0885,0095,5345,2055,0584,9804,6524,2784,1093,4693,3103,14303,2342,92103,0882,00400
       Accounts payable 
0
0
5,331
6,078
0
50,225
17,623
76,569
76,569
60,280
122,263
63,407
48,496
52,608
68,246
14,973
13,419
12,570
48,073
18,457
7,517
7,51718,45748,07312,57013,41914,97368,24652,60848,49663,407122,26360,28076,56976,56917,62350,22506,0785,33100
       Other Current Liabilities 
0
0
13,270
19,679
0
27,182
68,780
734,289
78,806
104,201
176,252
113,612
93,371
79,554
46,219
39,656
97,751
93,026
88,844
97,597
48,969
48,96997,59788,84493,02697,75139,65646,21979,55493,371113,612176,252104,20178,806734,28968,78027,182019,67913,27000
   > Long-term Liabilities 
0
0
145,336
162,820
0
150,032
552,387
0
151,726
153,777
112,032
113,960
106,985
113,172
170,994
169,975
94,157
89,622
84,989
75,587
70,342
70,34275,58784,98989,62294,157169,975170,994113,172106,985113,960112,032153,777151,7260552,387150,0320162,820145,33600
       Other Liabilities 
0
0
68,192
66,422
0
122,308
500,345
99,175
99,175
0
86,609
77,410
71,054
76,563
0
0
0
53,042
0
0
0
00053,04200076,56371,05477,41086,609099,17599,175500,345122,308066,42268,19200
       Deferred Long Term Liability 
0
0
966
0
0
0
1,034
0
0
0
515
0
0
0
302
0
0
0
0
0
0
0000003020005150001,03400096600
> Total Stockholder Equity
32,083
0
-42,802
-43,657
-43,657
761,350
711,347
711,347
835,318
695,294
688,476
674,858
623,202
624,988
533,253
713,399
649,047
602,265
517,367
446,914
376,755
376,755446,914517,367602,265649,047713,399533,253624,988623,202674,858688,476695,294835,318711,347711,347761,350-43,657-43,657-42,802032,083
   Common Stock
0
0
727
743
0
21,560
21,655
22,425
22,425
22,446
22,454
22,454
22,496
22,834
23,400
26,862
26,866
26,871
26,901
26,917
26,934
26,93426,91726,90126,87126,86626,86223,40022,83422,49622,45422,45422,44622,42522,42521,65521,560074372700
   Retained Earnings Total Equity000000000000000000000
   Accumulated Other Comprehensive Income 
32,083
0
472,418
495,397
-43,657
1,326,712
1,334,761
711,347
1,726,740
1,727,908
1,728,624
1,727,378
1,731,902
1,780,918
1,817,148
2,050,115
2,052,828
2,054,723
-67
2,056,531
-146
-1462,056,531-672,054,7232,052,8282,050,1151,817,1481,780,9181,731,9021,727,3781,728,6241,727,9081,726,740711,3471,334,7611,326,712-43,657495,397472,418032,083
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
461,542
495,397
0
1,326,712
1,334,761
1,726,740
-3,022
-211
-5,817
-3,096
-1,734
-1,734
-1,481
-344
0
2,054,723
2,057,805
0
2,060,050
2,060,05002,057,8052,054,7230-344-1,481-1,734-1,734-3,096-5,817-211-3,0221,726,7401,334,7611,326,7120495,397461,54200



6.3. Balance Sheets

Currency in EUR. All numbers in thousands.




6.4. Cash Flows

Currency in EUR. All numbers in thousands.




6.5. Income Statements

Currency in EUR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue52,656
Cost of Revenue-143,736
Gross Profit-91,080-91,080
 
Operating Income (+$)
Gross Profit-91,080
Operating Expense-185,142
Operating Income-276,222-276,222
 
Operating Expense (+$)
Research Development104,988
Selling General Administrative76,009
Selling And Marketing Expenses424
Operating Expense185,142181,421
 
Net Interest Income (+$)
Interest Income12,921
Interest Expense-2,493
Other Finance Cost-4,956
Net Interest Income5,472
 
Pretax Income (+$)
Operating Income-276,222
Net Interest Income5,472
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-254,640-297,803
EBIT - interestExpense = -278,715
-254,640
-252,341
Interest Expense2,493
Earnings Before Interest and Taxes (EBIT)-276,222-252,147
Earnings Before Interest and Taxes (EBITDA)-249,552
 
After tax Income (+$)
Income Before Tax-254,640
Tax Provision-67
Net Income From Continuing Ops-302,298-254,707
Net Income-254,834
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses328,878
Total Other Income/Expenses Net21,581-5,472
 

Technical Analysis of Curevac
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Curevac. The general trend of Curevac is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Curevac's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of CureVac NV.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.476 < 2.728 < 2.816.

The bearish price targets are: 2.43 > 2.43 > 2.11.

Tweet this
CureVac NV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of CureVac NV. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

CureVac NV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of CureVac NV. The current macd is -0.02731719.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Curevac price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Curevac. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Curevac price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
CureVac NV Daily Moving Average Convergence/Divergence (MACD) ChartCureVac NV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of CureVac NV. The current adx is 13.60.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Curevac shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
CureVac NV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of CureVac NV. The current sar is 2.762.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
CureVac NV Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of CureVac NV. The current rsi is 38.19. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
CureVac NV Daily Relative Strength Index (RSI) ChartCureVac NV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of CureVac NV. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Curevac price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
CureVac NV Daily Stochastic Oscillator ChartCureVac NV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of CureVac NV. The current cci is -158.67549669.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
CureVac NV Daily Commodity Channel Index (CCI) ChartCureVac NV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of CureVac NV. The current cmo is -31.53424907.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
CureVac NV Daily Chande Momentum Oscillator (CMO) ChartCureVac NV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of CureVac NV. The current willr is -80.92783505.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
CureVac NV Daily Williams %R ChartCureVac NV Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of CureVac NV.

CureVac NV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of CureVac NV. The current atr is 0.12478765.

CureVac NV Daily Average True Range (ATR) ChartCureVac NV Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of CureVac NV. The current obv is -441,024.

CureVac NV Daily On-Balance Volume (OBV) ChartCureVac NV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of CureVac NV. The current mfi is 45.89.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
CureVac NV Daily Money Flow Index (MFI) ChartCureVac NV Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for CureVac NV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-07-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

CureVac NV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of CureVac NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.185
Ma 20Greater thanMa 502.575
Ma 50Greater thanMa 1002.673
Ma 100Greater thanMa 2002.859
OpenGreater thanClose2.550
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Curevac with someone you think should read this too:
  • Are you bullish or bearish on Curevac? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Curevac? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about CureVac NV

I send you an email if I find something interesting about CureVac NV.


Comments

How you think about this?

Leave a comment

Stay informed about CureVac NV.

Receive notifications about CureVac NV in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.